Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine, the active ingredient in Ophtesic, is a local anesthetic presented as a sterile ophthalmic solution for topical ocular use. It provides rapid surface numbness to facilitate diagnostic examinations and minor eye procedures. GNH USA supplies Ophtesic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ophtesic, a lidocaine‑based ocular anesthetic, is used to provide temporary surface anesthesia for various eye procedures.

- Diagnostic eye examinations: numbs the ocular surface to allow comfortable slit‑lamp biomicroscopy. - Minor ocular surgery: facilitates painless corneal scraping, foreign‑body removal, or incision. - Laser procedures: reduces discomfort during laser photocoagulation or iridotomy.

Adverse reactions may occur following ocular administration of lidocaine.

Common Side Effects: - Transient burning or stinging sensation at the application site. - Mild ocular irritation or redness. - Temporary blurred vision. - Excessive tearing (epiphora). - Mild conjunctival hyperemia.

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis. - Corneal epithelial toxicity or ulceration. - Increased intra‑ocular pressure. - Persistent corneal ulceration or infection. - Severe ocular inflammation. - Systemic toxicity (e.g., CNS symptoms) in cases of overdose.

Careful assessment and monitoring are required when using Ophtesic.

- Allergy assessment: avoid if the patient has known hypersensitivity to amide‑type anesthetics. - Corneal integrity: use with caution on compromised corneas or epithelial defects. - Contact lens wearers: remove lenses before administration to prevent drug retention. - Systemic absorption: limit use in patients with severe cardiac conduction disorders. - Pregnancy and lactation: evaluate risk–benefit and use only if essential. - Store below 25°C: keep in the original container, protect from moisture and light.

Lidocaine may interact with other medications affecting cardiac conduction or metabolism.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may increase systemic lidocaine levels. - Beta‑blockers: potential additive effects on cardiac conduction.

Moderate Interactions (Monitor Closely): - Concurrent use of other local anesthetics: risk of cumulative toxicity. - CYP3A4 inhibitors (e.g., erythromycin): may alter lidocaine metabolism. - Systemic vasoconstrictors: may affect ocular blood flow and drug distribution.